Introduction
Biovail is a specialty pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture and commercialization of pharmaceutical products, utilizing advanced drug-delivery technologies. The company currently has over 20 distinct, proprietary drug-delivery technologies, and has access to other technologies through licensing agreements with development partners.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Biovail''s branded products in Canada include: Tiazac XC, Wellbutrin XL, Glumetza, Lescol, Lescol XL and Zyban. The company''s wholly-owned US subsidiary includes administrative, product distribution and related regulatory affairs functions. Its products include Cardizem CD, Ativan, Vaseretic, Vasotec, and Isordil.
Biovail derives its revenues primarily from the sales of pharmaceutical products developed and manufactured by the company, as well as sales of proprietary and in-license products;pharmaceutical clinical research and laboratory testing services, and product development activities in collaboration with third parties; The company''s total revenues increased at a CAGR of 7.9% during 2002-2006, from $788 million to $1,067.7 million. This represents an absolute total growth of +$279.7 million for total revenues. The increase is primarily attributable to increased product sales.
Reasons to Purchase
Access all the important information and analysis on the company in a single report
Understand company''s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company''s adjusted five year financial data along with key ratios and market capitalization
http://www.companiesandmarkets.com/information.asp?id=VCN2LQ4Y746009
CONTACT: Mike King, Director, www.companiesandmarkets.com Tel: +44 (0)1933 674 780 Fax: +44 (0)1933 674 780 e-mail: info@companiesandmarkets.com WWW:http://www.companiesandmarkets.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index